Evidence map›Paper›PMID 37966228›Full record

ArticleAntimicrobial agents and chemotherapy2023

Genome-scale analysis of essential gene knockout mutants to identify an antibiotic target process.

J Bailey, L Gallagher, C Manoil

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

J BaileyDepartment of Genome Sciences, University of Washington, Seattle, Washington, USA.
L GallagherDepartment of Genome Sciences, University of Washington, Seattle, Washington, USA.
C ManoilDepartment of Genome Sciences, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-6773-3434
University of Washington · US

Funding

Development of Antibiotic Adjuvants for Gram-Negative BacteriaR01AI136904 · NIAID · UNIVERSITY OF NOTRE DAME · PI MELANDER, CHRISTIAN COREY · 2018 to 2022
$3.7M
Microbial Ecology-Guided Discovery of Antibacterial DrugsR01AI162943 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Eric W Schmidt · 2022 to 2026
$3.2M
Defining the antibiotic intrinsic resistome of Acinetobacter baumanniiR01AI148208 · NIAID · UNIVERSITY OF WASHINGTON · PI MANOIL, COLIN · 2020 to 2021
$816k
NIAID NIH HHS R01 AI136904NIAID NIH HHS R01 AI148208NIAID NIH HHS R01 AI162943
6 · The paper itself

Abstract

We describe a genome-scale approach to identify the essential biological process targeted by a new antibiotic. The procedure is based on the identification of essential genes whose inactivation sensitizes a Gram-negative bacterium (

Indexed as

Anti-Bacterial AgentsGenes, EssentialDNA Transposable ElementsMeropenemPeptidoglycanAnti-Bacterial AgentsDNA Transposable ElementsMeropenemPeptidoglycanAcinetobactermeropenemnatural transformationTn-seq

Identifiers

PMID37966228
PMCPMC10720506
OpenAlexW4388698019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.